NCT00430651

Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)

Multicenter Randomized Phase III Study Comparing Docetaxel With Carboplatin Versus Docetaxel Single Agent as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (NSCLC).

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 135 (actual)
• Sponsor: Hellenic Oncology Research Group · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This trial will compare the effectiveness of Docetaxel with or without Carboplatin as second line chemotherapy in patients with Non-Small Cell Lung Cancer, who have not been treated previously with Docetaxel.

Conditions

• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Docetaxel	Docetaxel 50 mg/m2 IV on days 1 and 15 every 28 days for 6 cycles
DRUG	Carboplatin	Docetaxel 50 mg/m2 IV over 1 hour followed by Carboplatin 4 AUC IV over 1 hour on days 1 and 15

Timeline

• Start date: 2004-07-01
• Primary completion: 2008-05-01
• Completion: 2008-05-01
• First posted: 2007-02-02
• Last updated: 2009-01-28

Locations

10 sites across 1 country: Greece